alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 35 (Tuesday, February 23, 2010)]
[Notices]
[Page 8112]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3530]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 731-TA-130 (Third Review)]


Chloropicrin From China

AGENCY: United States International Trade Commission.

ACTION: Revised schedule for the subject review.

-----------------------------------------------------------------------

DATES: Effective Date: February 17, 2010.

FOR FURTHER INFORMATION CONTACT: Cynthia Trainor (202-205-3354), Office 
of Investigations, U.S. International Trade Commission, 500 E Street, 
SW., Washington, DC 20436. Hearing-impaired persons can obtain 
information on this matter by contacting the Commission's TDD terminal 
on 202-205-1810. Persons with mobility impairments who will need 
special assistance in gaining access to the Commission should contact 
the Office of the Secretary at 202-205-2000. General information 
concerning the Commission may also be obtained by accessing its 
internet server (http://www.usitc.gov). The public record for this 
investigation may be viewed on the Commission's electronic docket 
(EDIS) at http://edis.usitc.gov.

SUPPLEMENTARY INFORMATION: On October 15, 2009, the Commission 
established a schedule for the conduct of this review (74 FR 55065, 
October 26, 2009).
    Subsequently, counsel for three domestic interested parties filed a 
request to appear at the hearing or, in the alternative, for leave to 
submit written testimony in lieu of an oral presentation. In connection 
with the offer of written testimony, counsel indicated a willingness to 
respond to written questions of the Commissioners by a date to be set 
by the Commission. No other party filed a request to appear at the 
hearing. Consequently, the public hearing in connection with the 
review, scheduled to begin at 9:30 a.m. on February 18, 2010, at the 
U.S. International Trade Commission Building is cancelled.
    The Commission has determined to accept the offer to submit written 
testimony in lieu of an oral public hearing presentation. Written 
testimony shall be filed with the Commission by the close of business 
on Thursday, February 18, 2010. The parties are expected to respond to 
the Commission's written questions in their post-hearing briefs, which 
are due to be filed on March 1, 2010.
    For further information concerning this investigation see the 
Commission's notice cited above and the Commission's Rules of Practice 
and Procedure, part 201, subparts A through E (19 CFR part 201), and 
part 207, subparts A and C (19 CFR part 207).

    Authority:  This investigation is being conducted under 
authority of title VII of the Tariff Act of 1930; this notice is 
published pursuant to section 207.21 of the Commission's rules.

    By order of the Commission.

     Issued: February 17, 2010.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 2010-3530 Filed 2-22-10; 8:45 am]
BILLING CODE 7020-02-P
Editorial Note on Part 109
Editorial Note: Nomenclature changes to part 109 appear at 81 FR 49896, July 29, 2016.

§ 109.3 Definitions and interpretations. ( a ) *Act* means the Federal Food, Drug, and Cosmetic Act.
( b ) The definitions of terms contained in section 201 of the act are applicable to such terms when used in this part unless modified in this section.
( c ) A *naturally occurring poisonous or deleterious substance* is a poisonous or deleterious substance that is an inherent natural constituent of a food and is not the result of environmental, agricultural, industrial, or other contamination.
( d ) An *added poisonous or deleterious substance* is a poisonous or deleterious substance that is not a naturally occurring poisonous or deleterious substance. When a naturally occurring poisonous or deleterious substance is increased to abnormal levels through mishandling or other intervening acts, it is an added poisonous or deleterious substance to the extent of such increase.
( e ) *Food* includes human food and substances migrating to food from food-contact articles.
Editorial Note on Part 176
Editorial Note: Nomenclature changes to part 176 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; and 70 FR 72074, Dec. 1, 2005.

§ 176.120 Alkyl ketene dimers. Alkyl ketene dimers may be safely used as a component of articles intended for use in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting, or holding food, subject to the provisions of this section. ( a ) The alkyl ketene dimers are manufactured by the dehydrohalogenation of the acyl halides derived from the fatty acids of animal or vegetable fats and oils.
( b ) The alkyl ketene dimers are used as an adjuvant in the manufacture of paper and paperboard under such conditions that the alkyl ketene dimers and their hydrolysis products dialkyl ketones do not exceed 0.4 percent by weight of the paper or paperboard.
( c ) The alkyl ketene dimers may be used in the form of an aqueous emulsion which may contain sodium lignosulfonate as a dispersant.
[No. 38627-1-I.

Division One.

November 10, 1997.]

#### The State of Washington, *Respondent,*v. Donald Lee Fonville, *Appellant.*

Appeal from a judgment of the Superior Court for Snohomish County, No. 81-1-00680-3, Thomas J. Wynne, J., entered May 9, 1996. *Affirmed in part*and *reversed in part*by unpublished opinion per Cox, J., concurred in by Kennedy, A.C.J., and Webster, J.
###### Editorial Note on Part 180

#### Editorial Note:

Nomenclature changes to part 180 appear at 79 FR 75879, Dec. 19, 2014.

#### § 180.960 Ineligible or ineligibility.

*Ineligible or ineligibility* means that a person or commodity is prohibited from covered transactions because of an exclusion or disqualification.
1 / 142 / 143 / 144 / 145 / 146 / 147 / 148 / 149 / 1410 / 1411 / 1412 / 1413 / 1414 / 14
§ 26.63 General coverage of this part. ( a ) This part applies to conformity assessment procedures for products and/or processes and to other related cooperative activities as described in this part.
( b ) Subparts A and B of this part may include: ( 1 ) A description of the relevant legislative, regulatory, and administrative provisions pertaining to the conformity assessment procedures and technical regulations;
( 2 ) A statement on the product scope and coverage;
( 3 ) A list of designating authorities;
( 4 ) A list of agreed conformity assessment bodies (CAB's) or authorities or a source from which to obtain a list of such bodies or authorities and a statement of the scope of the conformity assessment procedures for which each has been agreed;
( 5 ) The procedures and criteria for designating the CAB's;
( 6 ) A description of the mutual recognition obligations;
( 7 ) A sectoral transition arrangement;
( 8 ) The identity of a sectoral contact point in each party's territory; and
( 9 ) A statement regarding the establishment of a Joint Sectoral Committee.
( c ) This part shall not be construed to entail mutual acceptance of standards or technical regulations of the parties and, unless otherwise specified in subpart A or B of this part, shall not entail the mutual recognition of the equivalence of standards or technical regulations.
#### § 1316.44 Waiver or modification of rules.

The Administrator or the presiding officer (with respect to matters pending before him) may modify or waive any rule in this subpart by notice in advance of the hearing, if he determines that no party in the hearing will be unduly prejudiced and the ends of justice will thereby be served. Such notice of modification or waiver shall be made a part of the record of the hearing.
# C o u rt o f

A p p ea ls

o f t h e S t a te o f

G eo rg ia

ATLANTA,_

_ _ __ _ _ __ _ __ _ _ _ _ _ __ _

Th e Co u rt

o f Ap p ea l s h er eb y p a s s es t h e f

o ll owi n g o r der :

A1 7 D0 15 9 . KEVI N J AMES v . MELANI E J AMES.

Kev i n J am es fi l ed t h i s ap p l i cat i on fo r d i s cret i o n a r y ap peal fro m an o rd er

d e n yi n g h i s m o t i o n to recu s e t he t ri al ju d g e fro m p o st -d i v o rce co n tem p t an d

m o di fi cat i o n p ro ceed i ng s

. 1 W e, h o wev er, l ack ju ri s d i ct i o n

. An o rd er d en y i n g a m o t i on t o recu s e i s i n terl o cu t o ry

. Mu r p h y v. Mu r p h y , 3 2 2

Ga. Ap p

. 8 2 9

, 8 30 (7 4 7 SE2 d 2 1 ) (2 01 3 ). In o rd er t o ap peal su ch an o r d er, an

ap p li can t m

u s t c om p ly w ith the inte r lo cu t o ry ap p eal p ro ced u re an d o b t ai n a cert i fi cat e

o f i m m ed i at e rev i ew. OCGA § 5 -6 -3 4 (b ). A l t h o u g h K e v i n J a m e s f i l e d a

d i s cret i o n ary ap p l i cat i on , “ [t ] h e d i scret i o n ary ap p eal s t at u t e d oes n o t ex cu s e a p art y

se ek i n g ap p el l at e rev i ew o f an i n t erl o cu t o ry o rd er fro m co m p l y i n g wi t h t h e ad d i t iona l

req u i rem en t s o f OCGA § 5-6 -3 4 (b ).” Ba i l ey v. Ba i l ey , 2 6 6 Ga. 8 3 2

, 8 3 3 (4 7 1 SE2 d

2 1 3 ) (1 9 9 6 ). Kev in J am es ’ s fai l u re t o fo l l o w th e p ro p er ap pel l at e p ro ced u re d ep ri v es

u s o f ju ri s d i ct i o n t o co n s i d er t h i s ap p l i cat i on

. 2 See W a r r in g er v. W

a rr in g er , 2 0 4 Ga.

A p p

. 8 6

, 8 6 (4 1 8 SE2 d 4 4 6 ) (1 9 9 2 ). A cco rd i n gl y , h i s ap p l i cat i on i s h ereb y

DISM ISSED.

1 Kev i n J am es o ri gi n al l y fi l ed hi s ap p li ca t i o n i n t h e Geo rg ia Su p rem e Co u rt

, wh i ch t ran s ferred t h e m at t er t o t h i s Co u rt

. See Cas e No

. S1 7 D0 3 1 6 (d eci d ed Oct o b er 1 2 , 2 0 1 6 ).

2 Ord ers d en y i n g m o t i o n s t o r e c us e m ay b e rev iewed aft er t he en t ry o f fi n al ju d g m en t

, as p art o f th e ap p eal fro m fi n al ju d g m en t

. See O CGA § 5 -6 -3 4 (d );

Mu r p h y , s u p ra at 8 3 0 -8 3 2. Here, Kev i n J am es ’ s ap p l icat io n w a s p r ed i cat ed o n t h e

t ri al co u rt ’ s o rd er d en y in g h i s recu s a l m o t i o n , an d it ap p ears th e cas e rem ai n ed

p en di n g wh en h e fi l ed h i s ap p li cat i o n

. See W a r r i n ger , s u p ra at 8 6

. November 14, 2016C o u r t o f A p p e a l s o f t h e S t a t e o

f G e o r g ia

C le r k ’ s O f f i c e

, A t la n t a

,

_

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ I c e r t i f y t h a t t h e a b o v e i s a tr u e e x t r a c t f r o m

t h e m i n u t e s o

f t h e C o u r t o

f A p p e a l s o f G e o r g i a

. W i tn e s s m y s i g n a t u r e a n d t h e s e a l o

f s a i d c o u r t

h e r e t o a f f i x e d t h e d a y a n d y e a r l a s t a b o v e w r i t t e n

.

, C l e r k

. 11/14/2016
§ 1.21 Failure to reveal material facts. ( a ) Labeling of a food, drug, device, cosmetic, or tobacco product shall be deemed to be misleading if it fails to reveal facts that are: ( 1 ) Material in light of other representations made or suggested by statement, word, design, device or any combination thereof; or
( 2 ) Material with respect to consequences which may result from use of the article under: ( i ) The conditions prescribed in such labeling or
( ii ) such conditions of use as are customary or usual.
( b ) Affirmative disclosure of material facts pursuant to paragraph (a) of this section may be required, among other appropriate regulatory procedures, by ( 1 ) Regulations in this chapter promulgated pursuant to section 701(a) of the act; or
( 2 ) Direct court enforcement action.
( c ) Paragraph (a) of this section does not: ( 1 ) Permit a statement of differences of opinion with respect to warnings (including contraindications, precautions, adverse reactions, and other information relating to possible product hazards) required in labeling for food, drugs, devices, cosmetics, or tobacco products under the Federal Food, Drug, and Cosmetic Act.
( 2 ) Permit a statement of differences of opinion with respect to the effectiveness of a drug unless each of the opinions expressed is supported by substantial evidence of effectiveness as defined in sections 505(d) and 512(d) of the act.
[42 FR 15553, Mar. 22, 1977, as amended at 77 FR 5176, Feb. 2, 2012]
Publication No. CH 604 TLMC

MODEL

CL-600-2B16 (CL-604)

A/C EFFECTIVITY

5301 TO 5665

Time Limits /

Maintenance Checks
CHALLENGER* 604

TIME LIMITS / MAINTENANCE CHECKS

Bombardier Aerospace

P. O. Box 6087, Station Centre-ville

Montreal, Quebec, Canada H3C 3G9

http://www.cic.bombardier.com

To ease the ordering process, the following Document

Identification Number should be used: CH 604 TLMC

It is understood that this documentation, comprising technical data and other information in any media

shall not be reproduced or disclosed in whole or in part without Bombardier's written authorization, is

proprietary and confidential to Bombardier and that all rights to patent, copyright, trademark, trade

secret and other intellectual property rights therein belong to Bombardier. Such documentation, 

technical data and other information shall not be modified, translated, reverse assembled, reverse

engineered or de-compiled and shall be used solely to maintain, operate or repair the aircraft.

Copyright © 1995-2011 by Bombardier Inc. All rights reserved.

*Trademark of Bombardier Inc. or its subsidiaries.

Printed in Canada

For more information regarding Technical Publications please contact:

Bombardier Customer Services Business Aircraft 

Customer Response Center (CRC)

North America: 1-866-JET-1247 (1-866-538-1247)

Outside North America: 1-514-855-2999

Fax: 1-514-855-2535

Email: bbad.user.comments@aero.bombardier.com

Distribution & Ordering

Fax: 1-514-855-2770

Email: bbad.pubs.dist@aero.bombardier.com
#### § 200.7 Supplying pharmacists with indications and dosage information.

There are presently no regulations under the Federal Food, Drug, and Cosmetic Act that prevent a manufacturer of prescription drugs from sending the pharmacist data he needs on indications and dosage in exercising his important professional function of checking against possible mistakes in a prescription. The Food and Drug Administration believes manufacturers should be encouraged to supply such printed matter to the pharmacist for his professional information. Obviously, such printed matter should not be displayed to prospective purchasers to promote over-the-counter sale of prescription drugs.
#### § 3.6 Product jurisdiction officer.

The Office of Combination Products (Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5129, Silver Spring, MD 20993-0002, 301-796-8930,, e-mail: *combination@fda.gov,* is the designated product jurisdiction officer.

[68 FR 37077, June 23, 2003, as amended at 71 FR 16033, Mar. 30, 2006; 75 FR 13678, Mar. 23, 2010]
Exhibit 10.22
 AMENDMENT TO THE EMPLOYMENT AGREEMENT
BETWEEN HARLAND CLARKE HOLDINGS CORP.
AND CHARLES DAWSON
 WHEREAS
 WHEREAS
 NOW, THEREFORE
 1.
    
    Section 2.1 is hereby modified by deleting the date of December 31, 2010 and
inserting in its place the date December 31, 2013.2.
    
    All other terms and conditions of the Employment Agreement shall otherwise
remain in place, except as expressly amended herein.
  HARLAND CLARKE HOLDINGS CORP.By:
    /s/ Peter FeraName:
    Peter FeraTitle:
    Chief Financial Officer/s/ Charles DawsonCharles Dawson Page 1of 1
Order entered July 13, 2022

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-22-00010-CV

FARMLAND PARTNERS INC., Appellant

V.

FIRST SABERPOINT CAPITAL MANAGEMENT, L.P., ET AL., Appellees

On Appeal from the 44th Judicial District Court

Dallas County, Texas

Trial Court Cause No. DC-21-08643

ORDER

Before the Court is appellees’ July 11, 2022 unopposed second motion for 

an extension of time to file their brief. We GRANT the motion and extend the 

time to August 3, 2022. We caution appellees that further extension requests will

be disfavored.

/s/ ROBERT D. BURNS, III

CHIEF JUSTICE
#### In re SANBORN.

(Supreme Court, Appellate Division, Second Department.

February 11, 1915.)

In the matter of Addison S. Sanborn, an attorney.

PER CURIAM.

Matter referred to Hon. William D. Dickey, as official referee. See, also, 158 App. Div. 939, 143 N. Y. Supp. 1142.

BURR, J., not voting.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1763 Sodium hydroxide. ( a ) Sodium hydroxide (NaOH, CAS Reg. No. 1310-73-2) is also known as sodium hydrate, soda lye, caustic soda, white caustic, and lye. The empirical formula is NaOH. Sodium hydroxide is prepared commercially by the electrolysis of sodium chloride solution and also by reacting calcium hydroxide with sodium carbonate.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a pH control agent as defined in § 170.3(o)(23) of this chapter and as a processing aid as defined in § 170.3(o)(24) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52444, Nov. 18, 1983]
§ 212.110 How must I maintain records of my production of PET drugs? ( a ) *Record availability.* Records must be maintained at the PET drug production facility or another location that is reasonably accessible to responsible officials of the production facility and to employees of FDA designated to perform inspections.
( b ) *Record quality.* All records, including those not stored at the inspected establishment, must be legible, stored to prevent deterioration or loss, and readily available for review and copying by FDA employees.
( c ) *Record retention period.* You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.
45.602-2 Reutilization Priorities.

(d) Dispose of the property identified in FAR Subpart 45.602-2(d) in accordance with DOD

Instruction 4161.02, Accountability and Management of Government Contract Property , dated April

27, 2012, and DOD Manual 4160.21, Volume 2, Defense Materiel Disposition: Property Disposal and

Reclamation , dated October 22, 2015.

Parent topic: 45.602 Reutilization of Government property.
# L_2019060EN.01003501.xml

| 28.2.2019 | EN | Official Journal of the European Union | L 60/35 |
| --- | --- | --- | --- |

28.2.2019

EN

Official Journal of the European Union

L 60/35

---

Corrigendum to Commission Regulation (EU) 2018/1497 of 8 October 2018 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards food category 17 and the use of food additives in food supplements

(
  Official Journal of the European Union L 253 of 9 October 2018
  )

On page 44, in the Annex, in the amendments to Annex II to Regulation (EC) No 1333/2008 after point 2(c), the following omission is corrected:

for:

| | ‘E 969 | Advantame | 55 | | only food supplements in syrup form’ |
| --- | --- | --- | --- | --- | --- |

‘E 969

Advantame

55

only food supplements in syrup form’

read:

| | ‘E 969 | Advantame | 55 | | only food supplements in syrup form |
| --- | --- | --- | --- | --- | --- |

‘E 969

Advantame

55

only food supplements in syrup form

| (d) | the entry for food subcategory 17.3 is deleted.’ |
| --- | --- |

(d)

---
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.185 TBHQ. The food additive TBHQ, which is the chemical 2-(1,1-dimethylethyl)-1,4-benzenediol (Chemical Abstracts Service Registry Number 1948-33-0), also known as tertiary butylhydroquinone, may be safely used in food in accordance with the following prescribed conditions: ( a ) The food additive has a melting point of not less than 126.5 °C.
( b ) The percentage of TBHQ in the food additive is not less than 99.0 percent when tested by the assay described in the Food Chemicals Codex, 9th ed. (2014), pp. 1192-1194, which is incorporated by reference, or an equivalent method. The Director of the Office of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the United States Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852 (Internet address: *http://www.usp.org*). Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030 or go to: *http://www.archives.gov/federal-register/cfr/ibr-locations.html*.
( c ) It is used as an antioxidant alone or in combination with BHA and/or BHT.
( d ) The total antioxidant content of a food containing the additive will not exceed 0.02 percent of the oil or fat content of the food, including the essential (volatile) oil content of the food.
[42 FR 14491, Mar. 15, 1977, as amended at 80 FR 34276, June 16, 2015; 88 FR 17719, Mar. 24, 2023]
Electronically Filed Intermediate Court of Appeals CAAP-16-0000673 23-MAY-2018 10:49 AM
Editorial Note on Part 13
Editorial Note: Nomenclature changes to part 13 appear at 88 FR 45065, July 14, 2023.

§ 13.40 Administrative record of a Board. ( a ) The administrative record of a hearing before a Board consists of the following: ( 1 ) All relevant Federal Register notices.
( 2 ) All written submissions under § 13.20.
( 3 ) The transcripts of all hearings of the Board.
( 4 ) The initial decision of the Board.
( b ) The record of the administrative proceeding is closed— ( 1 ) Relevant to receiving information and data, at the time specified in § 13.30(i); and
( 2 ) Relevant to pleadings, at the time specified in § 13.30(i) for filing a written statement of position with proposed findings and conclusions.
( c ) The Board may, in its discretion, reopen the record to receive further evidence at any time before filing an initial decision.